MOTS-c vs 5-Amino-1MQ

A 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene, with research interest in metabolic regulation, insulin sensitivity, and exercise capacity.

A first-in-class NNMT (nicotinamide N-methyltransferase) inhibitor that redirects cellular energy toward metabolic acceleration. Early clinical pipeline; widely used in biohacker fat-loss protocols.

MOTS-c moves between mitochondria, cytosol, and nucleus depending on metabolic state. It activates AMPK, improves glucose uptake, and regulates nuclear gene expression related to metabolic homeostasis. Circulating MOTS-c declines with age.

5-Amino-1MQ inhibits NNMT, reducing methyl-nicotinamide accumulation and increasing cellular NAD+/SAM levels. The downstream effect is improved metabolic throughput and reduced fat storage.

5–10 mg, 1–3 times per week (research protocols)

50–150 mg daily oral (research protocols)

~3 hours

Short — typically daily dosing

Subcutaneous

Oral

investigational

investigational

£30 · £3.0/mg via Peptides UK

Not yet listed